Biomarkers of Sleep-wake Cycle in Prodromal Alzheimer's Disease: Role in Cognitive Decline?

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Procedure, Other, Behavioral, Diagnostic test
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Alzheimer's disease (AD) is characterised by a progressive loss of memory and cognitive function. In the early stages of AD, there is a progressive accumulation of molecules: β-amyloid peptides (Aβ) in the brain. There is a link between the accumulation of Aβ peptides and the deterioration of sleep, but current knowledge does not confirmed this link. The objective of this study is to define whether there is a link between cognitive decline and sleep disorders. If a correlation is found, this could allow earlier treatment of sleep disorders in the longer term in order to slow the development of AD.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Maximum Age: 85
Healthy Volunteers: f
View:

• Diagnosis of mild Alzheimer's disease with a Mini Mental State (MMS) between 21-30

• The presence of a family carer to complete neuropsychological scales, questionnaires and sleep diaries

• Having a neurological assessment and/or follow-up requiring blood and cerebrospinal fluid (CSF) sampling with biomarkers for diagnostic purposes

• Patient who had a lumbar puncture less than one year ago or patient with a scheduled lumbar puncture as part of care

• Signed informed consent

• Able to carry out all visits and follow study procedures

• Affiliation to the French social security system

Locations
Other Locations
France
University Hospital, Montpellier
RECRUITING
Montpellier
University Hospital of Poitiers
NOT_YET_RECRUITING
Poitiers
University Hospital of Toulouse
NOT_YET_RECRUITING
Toulouse
Contact Information
Primary
Claire Denis
claire-denis@chu-montpellier.fr
+33467333162
Backup
Yves Dauvilliers, MD
y-dauvilliers@chu-montpellier.fr
+33467335219
Time Frame
Start Date: 2023-04-17
Estimated Completion Date: 2027-07-01
Participants
Target number of participants: 132
Treatments
Experimental: Single arm
Alzheimer
Related Therapeutic Areas
Sponsors
Collaborators: Institut National de la Santé Et de la Recherche Médicale, France
Leads: University Hospital, Montpellier

This content was sourced from clinicaltrials.gov